Navigation Links
Voices Against Brain Cancer Awards Grant to Tocagen to Support Investigation of Toca 511 & Toca FC in Patients with Recurrent Brain Cancer
Date:6/19/2013

NEW YORK, June 19, 2013 /PRNewswire/ -- Voices Against Brain Cancer (VABC), a not-for-profit organization dedicated to finding a cure for brain cancer, today announced that it has awarded Tocagen Inc. (www.tocagen.com) a grant to support the clinical investigation of Toca 511 & Toca FC in patients diagnosed with a recurrent high grade glioma brain cancer (Grade 3 or Grade 4).  Tocagen is a privately held biopharmaceutical company developing novel treatments for advanced cancer, with an initial focus on brain cancer.

"Every day, progress is made in the search for a cure for this devastating disease," said Mario Lichtenstein, Co-founder of Voices Against Brain Cancer.  "Toca 511 & Toca FC is a promising new approach in clinical trials that has the potential to help patients with brain cancer, and we are excited to provide support for this program."

Tocagen is presently enrolling patients in its investigational Phase I clinical trials at leading clinical trial sites across the United States. For more information about participating in this study, please submit an inquiry form to Tocagen.

"We are very appreciative to VABC for supporting our clinical trials in patients with recurrent brain cancer," said Harry Gruber, M.D., the CEO of Tocagen. "We are encouraged with our clinical data and plan to present updates at a future scientific conference."

For press inquiries, please contact: 5W Public Relations.

About Voices Against Brain Cancer
Voices Against Brain Cancer's mission is to help find a cure for brain cancer and brain tumors by advancing scientific research, increasing awareness within the medical community and supporting patients, their families and caregivers affected by this devastating disease.

Voices Against Brain Cancer has a wide variety of initiatives in place for brain cancer research, awareness and support. The organization is committed to ensuring that the proceeds of the monies donated are used to fund cutting-edge research that will have a monumental impact on the diagnosis and treatment of brain cancer. Currently, these grants are being funded at numerous esteemed institutions including: Columbia, Cornell, Duke, Harvard, John Hopkins, MD Anderson, Memorial Sloan Kettering, New York University, Yale and more.

For more information please visit: www.voicesagainstbraincancer.org

About Toca 511 & Toca FC
Tocagen Inc., the clinical trial sponsor, is developing the investigational drug Toca 511 (vocimagene amiretrorepvec) in combination with Toca FC (an investigational extended-release formulation of 5‑FC) for the treatment of recurrent high grade glioma, including glioblastoma multiforme (GBM, Grade IV glioma), the most common and aggressive form of brain cancer. Toca 511 is a retroviral replicating vector (RRV) encoding the genetic instructions for the enzyme cytosine deaminase (CD). Toca 511 is designed to selectively infect dividing cancer cells and spread through the tumor after administration. Each patient then begins a course of Toca FC. Within Toca 511-infected cells the CD enzyme converts 5‑FC to the anti-cancer drug 5‑FU. By producing 5‑FU locally, this technology has the potential to produce much higher concentrations of 5‑FU in the tumor than can be safely attained with systemic administration.


'/>"/>
SOURCE Voices Against Brain Cancer
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. United Spinal To "Roll on Capitol Hill:" Voices Aim to Impact Federal Health Care Policy
2. WAISMANN METHOD® Medical Director Voices Support for Fibromyalgia Awareness Day
3. Inovios Universal H7N9 DNA Vaccine Generates First Protective Antibody Responses Against Virulent H7N9 Virus in 100% of Vaccinated Animals
4. Elan ADS Holders Decisively Vote Against Theravance And AOP Transactions
5. The World Customs Organization (WCO) and the Institute of Research Against Counterfeit Medicines (IRACM) issue a new warning about the health and safety of African populations
6. Consumer Watchdog: United Healthcare Sued for Discriminating Against HIV/AIDS Patients
7. PDL Files for Arbitration Against Genentech Based on Underpayment of Royalties
8. Royalty Pharma Urges Elan Shareholders to Vote AGAINST ALL FOUR Elan Resolutions Today
9. Bernstein Liebhard LLP Announces That a Class Action Has Been Filed Against Intuitive Surgical, Inc.
10. Bernstein Liebhard LLP Announces That A Class Action Has Been Filed Against Invacare Corporation
11. ResMed Takes Action to Enforce Patents Against BMC and 3B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Research and Markets has announced the addition ... report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and ... global Fibromyalgia market. The research answers the following questions: ... Fibromyalgia and their clinical attributes? How are they positioned in the ...
(Date:2/23/2017)... Feb. 23, 2017 Regulus Therapeutics Inc ... and development of innovative medicines targeting microRNAs, today announced ... financial results on Thursday, March 2, 2017 after the ... call and webcast on March 2, 2017 at 5:00 ... year 2016 financial results and provide a general business ...
(Date:2/23/2017)... PUNE, India , February 23, 2017 ... "Diagnostic Imaging Market by Product (X-ray Imaging Digital, Analog), ... PET)), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, ... MarketsandMarkets, the report studies the global market over the ... expected to reach ~USD 36.43 Billion by 2021, at ...
Breaking Medicine Technology:
(Date:2/23/2017)... (PRWEB) , ... February 23, 2017 , ... ... thought leadership , media relations, content marketing, social media management, corporate communications, ... clients already in the state and in nearby New Hampshire, Massachusetts and Canada, ...
(Date:2/23/2017)... ... , ... Dr. David Mahon leads Siena Dental, a comprehensive dental practice located ... 2017 Top Patient Rated Henderson Dentist by Find Local Doctors earlier this ... and dentists who have earned high ratings and superior patient reviews from multiple credible ...
(Date:2/23/2017)... , ... February 23, 2017 , ... ... announced today that it will soon begin franchising throughout the U.S. starting this ... to help bring the practice of meditation mainstream. Current Meditation will be the ...
(Date:2/23/2017)... VA – , ... ... coming. It’s the perfect opportunity for the nation to come ... a college basketball bracket – with its favorite fruit – ... is encouraging apple lovers to join the “Apple Madness” bracket ...
(Date:2/23/2017)... ... ... Curemark, LLC announced today that the Blüm Study, a Phase 3 clinical ... Autism, is now enrolling at three new sites. These new sites are in addition ... “There are currently no approved drugs that address the core symptoms of autism,” said ...
Breaking Medicine News(10 mins):